Invitrogen to buy BioSource for $130M

Invitrogen, a maker of tools used to develop biotechnology drugs, agreed to buy life sciences company BioSource International for $130 million in cash, the companies said on Tuesday. Invitrogen said the deal bolsters its research capabilities and allows it to enter new markets in immunology, oncology and neurodegenerative disease.

"The acquisition of BioSource enables our company to continue its growth in the vital area of proteomics," said Gregory T. Lucier, chairman and CEO of Invitrogen. "Moreover, the potential combination of BioSource's strength in technology development and our leading brand positions us to achieve an important goal of developing a collection of disease specific tools."

- read this AP report for more

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.